QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: How RMS and CMS Roles Work Together in MRP and DCP

Test your understanding of the concepts covered by How RMS and CMS Roles Work Together in MRP and DCP.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which record would best support later reconstruction of an important regulatory decision?

Only the final authorisation date and the name of the RMS. Only the final agreed product information. The issue raised, supporting evidence, response, conclusion and effect on the regulatory position. A list of all emails without identifying the scientific issue discussed.

Question 2 of 10 What is the most appropriate role of the RMS when coordinating applicant responses to CMS questions?

To prevent CMSs from seeing the applicant's responses. To coordinate assessment of the responses within the common procedure while preserving CMS participation. To convert all responses into separate national scientific positions. To decide that applicant responses are administrative and outside scientific assessment.

Question 3 of 10 After completion of a DCP, a team describes the outcome as 'one authorisation valid in five countries.' What is the most accurate correction?

There are coordinated national marketing authorisations resulting from a common procedure. There is no authorisation until the RMS issues an EU-wide decision. There are five unrelated authorisations with no common scientific basis. There is one authorisation owned by the RMS and five local copies.

Question 4 of 10 During the procedure, a CMS identifies an important uncertainty in the clinical evidence. What is the most appropriate next step within the RMS/CMS model?

The CMS should suppress the concern because the RMS owns the assessment. The CMS should raise and substantiate the concern through the applicable procedure. The CMS should issue a unilateral EU-wide refusal. The CMS should negotiate a separate scientific position directly with each other Member State.

Question 5 of 10 What would be the clearest indication that a CMS is performing its intended role rather than merely endorsing the RMS?

The CMS accepts every RMS conclusion without comment. The CMS limits its review to formatting and document completeness. The CMS reviews the assessment, raises questions where appropriate and evaluates the resulting regulatory position. The CMS repeats the entire assessment independently without using the RMS report.

Question 6 of 10 A regulatory professional reviewing a legacy file finds no record of how a major CMS safety concern was resolved. What is the principal deficiency?

The absence of a national authorisation automatically invalidates the product. The file lacks traceability between the concern, evidence, responses and final regulatory conclusion. The RMS should have been replaced by the applicant. CMS concerns are not required to be documented if the procedure concluded.

Question 7 of 10 What is the applicant's most appropriate communication strategy during an MRP or DCP?

Maintain one coherent scientific and regulatory position while addressing procedural and national matters appropriately. Treat every Member State as an unrelated negotiation and submit different scientific positions to each. Communicate only with the RMS and disregard CMS comments. Allow each national affiliate to modify the scientific rationale independently.

Question 8 of 10 A competent authority acts as RMS for one product procedure and as CMS for another. What is the most appropriate interpretation?

The authority has changed its permanent regulatory status. The authority is acting inconsistently with the EU regulatory system. RMS and CMS designations are procedural roles that may differ across products and procedures. An authority may act as RMS only once and must thereafter remain a CMS.

Question 9 of 10 Which statement about a CMS disagreement is most consistent with the article?

Every disagreement automatically becomes the same formal referral procedure. A CMS concern can be ignored if the RMS considers the assessment adequate. The applicable pathway depends on the nature and stage of the issue and the governing legal framework. CMSs may express concerns only after national authorisations have been granted.

Question 10 of 10 Why can a change to a warning in product information require more than editorial review?

All product-information changes are legally irrelevant once the dossier is submitted. Wording may reflect a substantive conclusion about evidence, safety or risk minimisation. Only the applicant can determine whether wording is scientific. CMSs are not permitted to review product information.

QPPV.com

Knowledge Assessment: How RMS and CMS Roles Work Together in MRP and DCP

Cookie Settings